- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07784478
Effect of Oxytocin Bolus Versus Slow Infusion on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia
Effect of Oxytocin Administration Technique on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia: A Randomised Controlled Trial
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Postpartum haemorrhage remains a leading cause of maternal mortality worldwide. Oxytocin is the first-line uterotonic agent used after delivery of the baby during caesarean section. When given as a rapid intravenous bolus, oxytocin can cause significant hypotension, tachycardia and other haemodynamic changes, especially in women under spinal anaesthesia.
This prospective, randomised, controlled trial will compare the haemodynamic effects of oxytocin 5 IU administered as a rapid intravenous bolus versus the same dose given as a slow intravenous infusion over 15 minutes in women undergoing elective caesarean section under spinal anaesthesia.
Sixty women aged 18-40 years with singleton pregnancy at 37-42 weeks, ASA physical status I or II, will be randomly allocated to one of two groups:
Group A (Bolus): Oxytocin 5 IU given as an intravenous bolus over 15 seconds immediately after umbilical cord clamping.
Group B (Infusion): Oxytocin 5 IU diluted and infused over 15 minutes via syringe pump immediately after umbilical cord clamping.
The primary outcome is the change in systolic blood pressure from baseline at 2, 5 and 10 minutes after oxytocin administration. Secondary outcomes include changes in diastolic blood pressure and heart rate, incidence of hypotension and tachycardia, vasopressor requirements, uterine tone assessed by a 5-point scale, estimated blood loss, and side effects such as nausea, vomiting, flushing and chest discomfort.
The study will be conducted at Hayatabad Medical Complex, Peshawar. All participants will receive standard spinal anaesthesia and routine care. The results are expected to provide local evidence to support safer oxytocin administration practices during caesarean section under spinal anaesthesia.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Fareeha Zahir, MBBS / FCPS-II Trainee
- Telefoonnummer: +923319932275
- E-mail: fareehak933@gmail.com
Studie Locaties
-
-
Khyber Pakhtunkhwa
-
Peshawar, Khyber Pakhtunkhwa, Pakistan, 25000
- Hayatabad Medical Complex / Khyber Girls Medical College
-
Contact:
- Fareeha Zahir, MBBS / FCPS-II Trainee
- Telefoonnummer: +923319932275
- E-mail: fareehak933@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Adult female patients aged 18 to 40 years
- American Society of Anesthesiologists (ASA) physical status class I or II
- Singleton pregnancy at 37 to 42 weeks gestational age
- Scheduled for elective caesarean section under spinal anaesthesia
- Written informed consent obtained
Exclusion Criteria:
- Patients with anticipated hemodynamic instability including severe preeclampsia/eclampsia, placenta previa with active bleeding, placental abruption, or hemorrhagic shock
- Pre-existing cardiovascular disease including ischemic heart disease, valvular heart disease, cardiomyopathy, or arrhythmias
- Baseline systolic blood pressure < 100 mmHg or heart rate > 100 bpm before spinal block
- Known hypersensitivity to oxytocin
- Failed spinal anaesthesia requiring conversion to general anaesthesia
- Patients receiving medications that may alter the hemodynamic response to oxytocin (beta-blockers, calcium channel blockers, ACE inhibitors, or angiotensin receptor blockers)
- Pre-existing anaemia (Hb < 8 g/dL)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Bolus Group
Participants will receive oxytocin 5 IU in 1 mL normal saline as an intravenous bolus over 15 seconds immediately after umbilical cord clamping, followed by 9 mL normal saline infusion over 15 minutes (to maintain blinding).
|
Oxytocin 5 IU administered either as a rapid intravenous bolus over 15 seconds or as a slow intravenous infusion over 15 minutes immediately after umbilical cord clamping during elective caesarean section under spinal anaesthesia.
Andere namen:
|
|
Experimenteel: Infusion Group
Participants will receive oxytocin 5 IU diluted in 50 mL normal saline administered via syringe pump over 15 minutes immediately after umbilical cord clamping.
A simultaneous 1 mL normal saline bolus will be given over 15 seconds to maintain blinding of the initial injection.
|
Oxytocin 5 IU administered either as a rapid intravenous bolus over 15 seconds or as a slow intravenous infusion over 15 minutes immediately after umbilical cord clamping during elective caesarean section under spinal anaesthesia.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Systolic Blood Pressure (SBP) from Baseline
Tijdsspanne: Baseline; 2 minutes, 5 minutes, and 10 minutes after oxytocin administration
|
Change in systolic blood pressure from baseline (mean of three pre-anaesthesia readings) measured at 2, 5, and 10 minutes after oxytocin administration.
|
Baseline; 2 minutes, 5 minutes, and 10 minutes after oxytocin administration
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Diastolic Blood Pressure and Heart Rate from Baseline
Tijdsspanne: 1, 2, 3, 5, 10, 15, and 20 minutes after oxytocin administration
|
Change in diastolic blood pressure and heart rate from baseline at defined time points after oxytocin administration.
|
1, 2, 3, 5, 10, 15, and 20 minutes after oxytocin administration
|
|
Incidence of Clinically Significant Hypotension
Tijdsspanne: Within 20 minutes after oxytocin administration
|
Proportion of participants who develop systolic blood pressure < 90 mmHg or a fall of > 20% from baseline after oxytocin administration.
|
Within 20 minutes after oxytocin administration
|
|
Uterine Contraction Scale Score
Tijdsspanne: 5 minutes after placental delivery
|
Uterine tone assessed by the operating obstetrician using a 5-point scale (Grade 1 = atonic to Grade 5 = very well contracted) at 5 minutes after placental delivery.
Grade 1 or 2 is classified as uterine atony.
|
5 minutes after placental delivery
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Vaatziekten
- Hart-en vaatziekten
- Pathologische processen
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Verloskundige arbeidscomplicaties
- Zwangerschap Complicaties
- Bloeding
- Puerperale aandoeningen
- Bloeding van de baarmoeder
- Pathologische aandoeningen, tekenen en symptomen
- Hypotensie
- Post-partumbloeding
- Hormonen
- Hormonen, hormoonvervangers en hormoonantagonisten
- Peptide hormonen
- Peptiden
- Aminozuren, peptiden en eiwitten
- Hypofysehormonen, posterieur
- Hypofysehormonen
- Oxytocine
Andere studie-ID-nummers
- CHR-IREB-2026-0050
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .